European Archives - Page 1041 of 1260 - European Medical Journal

Minimal Residual Disease Monitoring by Digital PCR for JAK2V617F Detection in Patients with Myelofibrosis or Acute Myeloid Leukaemia Secondary to Myelofibrosis after Allogeneic Stem Cell Transplantation

Myelofibrosis (MF) is one of the BCR-ABL1-negative chronic myeloproliferative neoplasms (MPNs), characterised by clonal expansion of abnormal…

The Role of Allograft in Acute Lymphoblastic Leukaemia, Including Alternate Donors

The management of acute lymphoblastic leukaemia (ALL) remains challenging.

Double-Hit and Triple-Hit Lymphomas: New Perspectives for Their Classification

In 2016, an update on the classification of lymphoid neoplasm was published, and one of the modifications made focussed on B-cell lymphoma…

Management of Adult Patients with Myelodysplastic Syndromes

The myelodysplastic syndromes form a heterogeneous group of clonal disorders with an increasing incidence in the elderly population and an emerging…

Different Therapeutic Interventions and Mechanisms of Action of Antisickling Agents Currently in Use in Sickle Cell Disease Management

Sickle cell disease is a genetic disorder caused by sickle haemoglobin. In many forms of the disease, the red blood cells can change shape upon…

Networking with Neurology Attending Congress: A First Timer’s Perspective

If you had asked me what the word congress meant to me a year ago, the connotations would have been extremely different to those which I picture today.

Link Established Between Iron Status and Coronary Artery Disease

IRON may have protective qualities against heart disease, suggests a new study examining iron levels in relation to coronary artery disease (CAD), by a…

3D-Printed Models: The Future of Heart Valve Replacement

OUTCOMES of heart valve replacements could be revolutionised through the use of three-dimensional (3D)-printed models, which could boost the success of…

EMJ

More Frequent Haemodialysis Improved Outcomes: The Wish Comes True at Home

This satellite symposium reviewed the challenges in providing dialysis to patients with kidney disease and outlined data supporting the effectiveness of…

Helsinn Group and MEI Pharma Announce First Patient Dosed in Pivotal Phase 3 Study of Pracinostat and Azacitidine in Acute Myeloid Leukemia

Lugano, Switzerland and San Diego, USA, 2 August, 2017 – Helsinn, a Swiss pharmaceutical group focused on building quality cancer care products…